Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Atherosclerosis / Coronary Artery Disease (CAD) / Coronary Heart Disease (CHD) / Ischemic Heart Disease (IHD) & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Current knowledge of the role of a protective immune response in atherosclerotic lesions has provided promising opportunities to develop new immunotherapeutic strategies.
Tabares-Guevara et al. 2021 Immunotherapy 13: 1231-1244

In particular, Tregs exert an atheroprotective role by releasing anti-inflammatory cytokines (IL-10/TGF-β) and suppressing autoreactive T lymphocytes.
Tabares-Guevara et al. 2021 Immunotherapy 13: 1231-1244

In vivo animal experiments have shown that this can be achieved by developing vaccines that stimulate immunological tolerance to atheroma antigens.
Tabares-Guevara et al. 2021 Immunotherapy 13: 1231-1244…

References (Sources)

Atherosclerosis: immunopathogenesis and strategies for immunotherapy
Tabares-Guevara et al. 2021 Immunotherapy 13: 1231-1244
Review
Initial Invasive or Conservative Strategy for Stable Coronary Disease
Maron et al. 2020 NEJM 382: 1395-1407
New targets and mechanisms of action for lipid-lowering and anti-inflammatory therapies in atherosclerosis: where does the field stand?
Nicholls & Nelson 2024 Expert Opinion on Therapeutic Targets 28(5): 375-384
Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis
Wang et al. 2015b Cell 163(7): 1585-1595
Novel emerging therapies in atherosclerosis targeting lipid metabolism
Gupta et al. 2020d Exp Opin Inv drugs 29: 611-622
Review
Targeting Trimethylamine N-Oxide: A New Therapeutic Strategy for Alleviating Atherosclerosis
Jing et al. 2022 Front. Cardiovasc. Med. 9: 864600
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: